Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...
Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...
The FDA canceled a vaccine advisory committee meeting to discuss influenza virus strains that should be included in shots for the next flu season ...
The second vaccine, developed by Moderna in partnership with the National ... does not require time-consuming steps, such as growing ingredients in chicken eggs. Pfizer invested $2 billion of ...
The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological disorder. The phase 3 study is evaluating the candidate, dubbed mRNA-1403 ...
Moderna did not include potential sales for new products, including its next-generation Covid-19 vaccine, in its 2025 estimates. The team was asked whether this was a reflection of any uncertainty ...
(Reuters) -Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a rare neurological side effect was reported. The trial of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback